ARALEZ PHARMACEUTICALS INC. announced unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2017. For the quarter, the company reported total revenues, net was $24,338,000 as compared to $13,628,000 same period last year. Loss from operations was $17,441,000 as compared to $19,634,000 same period last year. Loss before income taxes was $24,160,000 as compared to $20,302,000 same period last year. Net loss was $24,441,000 or $0.37 per share basic and diluted as compared to $20,599,000 or $0.32 per share basic and diluted same period last year. Adjusted EBITDA was $377,000 as compared to loss of $12,285,000 same period last year.

For the months, the company reported total revenues, net was $77,925,000 as compared to $134,263,000 same period last year. Loss from operations was $58,544,000 as compared to $74,379,000 same period last year. Loss before income taxes was $78,123,000 as compared to $71,420,000 same period last year. Net loss was $79,438,000 or $1.20 per share basic and diluted as compared to $71,862,000 or $1.26 per share basic and diluted same period last year. Adjusted LBITDA was $6,605,000 as compared to loss of $35,677,000 same period last year.

The company provides updated earnings guidance for the year ending December 31, 2017 and preliminary guidance for full year ended December 31, 2018. The company now expect net revenues of $95 million to $105 million compared to previous guidance of $80 million to $100 million. Adjusted LBITDA to be $5 million. Net loss to be in the range of $104.500 million to $95 million. Depreciation and amortization expense to be in the range of $36 million to $35 million. Interest expense to be in the range of $27 million to $26 million.

For the year 2018, the company expects net revenues to be in the range of $140 million to $160 million. Adjusted EBITDA to be in range of $35 million to $55 million. Net loss to be in the range of $56 million to $33 million. Depreciation and amortization expense to be in the range of $36 million to $35 million. Interest expense to be in the range of $27 million to $26 million.